8-K: Ensysce Biosciences Reports Positive Q3 Results Driven by NIH Grant and Clinical Progress

Ensysce Biosciences announced its third quarter 2024 financial results, highlighted by a $14 million NIH grant and advancements in clinical trials for its pain management therapies.

Summary

• Ensysce Biosciences reported its financial and operational results for the third quarter ended September 30, 2024.
• The company received a $14 million multi-year grant from the NIH to support the clinical development of PF614-MPAR, an opioid with oral overdose protection.
• A second Phase 1b trial, PF614-MPAR-102, has been initiated with the NIH funding.
• The company submitted its Phase 3 protocol for PF614 to the FDA for review, with feedback expected by the end of November.
• Ensysce raised $5 million in gross proceeds through a financing transaction in August, which will be used to advance clinical site selection for the Phase 3 trial.
• Cash and cash equivalents increased to $4.2 million as of September 30, 2024, compared to $1.1 million at the end of 2023, primarily due to $8.5 million in equity financings.
• Stockholders equity was $6.6 million as of September 30, 2024, meeting Nasdaq listing requirements.
• Federal grant funding totaled $3.4 million for the third quarter of 2024, compared to $0.4 million in the same period last year.
• Research and development expenses were $1.7 million for the third quarter of 2024, a decrease of $0.2 million compared to the same period in 2023.
• The company reported a net income of $0.7 million for the third quarter of 2024, compared to a net loss of $2.7 million for the same period in 2023, due to the timing of federal grant funding.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant progress in clinical trials, a substantial NIH grant, and improved financial results. The company is making strides in addressing a critical need in the pharmaceutical industry, which is viewed favorably.

Positives

• The $14 million NIH grant provides significant funding for the development of PF614-MPAR.
• The initiation of the second Phase 1b trial for PF614-MPAR demonstrates progress in clinical development.
• The submission of the Phase 3 protocol to the FDA is a key step towards regulatory approval.
• The increase in cash and cash equivalents provides financial stability for ongoing operations.
• The company achieved net income in the third quarter of 2024, a positive shift from previous losses.
• The company is compliant with Nasdaq listing requirements for stockholders equity.

Negatives

• Research and development expenses decreased by $0.2 million, which may indicate a slowdown in some areas of research.
• The company expects federal grant funding to decline in coming quarters after the completion of the OUD grant.
• The company anticipates that net income for the third quarter is a one-time event and expects losses in future quarters.
• The company is a clinical stage biotech company and expects to incur losses for the foreseeable future.

Risks

• The company's product candidates are in clinical trials and there is no guarantee of success in demonstrating safety and efficacy.
• There is a risk of delays in clinical development and regulatory approvals.
• The company may face challenges in commercializing its product candidates.
• The company's ability to fund its continued operations, including planned clinical trials, is subject to risks.
• The company is subject to risks and uncertainties, including possible NASDAQ delisting.

Future Outlook

The company anticipates the results from ongoing clinical studies will continue to build on prior positive safety data to bring its innovative pain products to market. They also plan to advance their opioid use disorder program into clinical development in the coming years. The company expects to receive FDA feedback on their Phase 3 protocol by the end of November and to execute the study over the coming year. They expect research and development expenses to increase in coming quarters due to increased activities on the OUD and MPAR programs. They also expect federal grant funding to decline in coming quarters and do not anticipate net income in coming quarters.

Management Comments

• Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, 'Our team has made significant progress in the third quarter, and we have line of sight to meaningful clinical initiatives to close out the year.'
• Dr. Kirkpatrick stated, 'The highlight of the third quarter was NIHs recognition of the potential value provided by our overdose protection technology MPAR, by awarding Ensysce with a $14 million multi-year grant to further the clinical development of PF614-MPAR.'
• Dr. Kirkpatrick continued, 'We also built on FDA feedback from our End of Phase 2 meeting in February to complete our Phase 3 protocol and have submitted it to the FDA.'

Industry Context

This announcement is significant in the context of the ongoing opioid crisis, as Ensysce is developing innovative solutions to reduce the potential for opioid abuse and overdose. The company's focus on abuse-deterrent and overdose-resistant technologies aligns with the growing need for safer pain management options. The NIH grant underscores the importance of these technologies and the potential impact they could have on public health.

Comparison to Industry Standards

• Ensysce's focus on abuse-deterrent and overdose-resistant opioid formulations is a key differentiator in the pharmaceutical industry, where there is a growing need for safer pain management options.
• Companies like Collegium Pharmaceutical and BioDelivery Sciences International also focus on abuse-deterrent opioid formulations, but Ensysce's MPAR technology provides an additional layer of overdose protection.
• The $14 million NIH grant is a significant achievement for a company of Ensysce's size, indicating strong support for their technology and approach.
• The submission of the Phase 3 protocol to the FDA is a critical step in the regulatory process, and the company's ability to execute this study will be a key factor in its success.
• The company's financial results show a positive trend with increased cash and a net income for the quarter, which is a positive sign for investors.

Stakeholder Impact

• Shareholders will benefit from the positive financial results and clinical progress.
• Employees will be impacted by the company's growth and development.
• Patients suffering from severe pain will potentially benefit from the company's innovative pain management solutions.
• The company's technology could help reduce the risk of opioid abuse and overdose, benefiting society as a whole.

Next Steps

• The company expects FDA feedback on the Phase 3 protocol for PF614 by the end of November.
• Ensysce plans to execute the Phase 3 study over the coming year.
• The company will continue to advance its opioid use disorder program into clinical development.
• The company will continue to work with Quotient Sciences to perfect the drug product.

Key Dates

Keywords

Ensysce Biosciences, PF614, PF614-MPAR, opioid, pain management, clinical trial, NIH grant, FDA, overdose protection, TAAP, MPAR, OUD, biotech, pharmaceutical